07/11/2013
EnVivo Pharmaceuticals Announces Appointment of Deborah Dunsire, M.D., as President and Chief Executive Officer

03/07/2013
EnVivo Pharmaceuticals Announces Appointment of Robert Weisskoff, Ph.D., as Interim Chief Executive Officer

02/28/2013
EnVivo Pharmaceuticals Announces Initiation of Phase 3 Clinical Trial Program of EVP-6124 in Schizophrenia

01/03/2013
EnVivo Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial Program of EVP-0962 in Alzheimer’s Disease

10/31/2012
EnVivo Pharmaceuticals Presents Additional EVP-6124 Phase 2b Clinical Trial Results at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

07/18/2012
EnVivo Pharmaceuticals Announces Statistically Significant Improvement in Cognition and Clinical Function in Phase 2b Clinical Trial in Alzheimer’s Disease

06/13/2012
EnVivo Pharmaceuticals to Present Phase 2b Clinical Data of Lead Program in Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2012

05/22/2012
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of Directors

04/19/2012
EnVivo Pharmaceuticals Names Christopher L. Burnley Chief Business Officer

12/13/2011
EnVivo Pharmaceuticals Announces Neuropharmacology Publication, Confirms Novel Mechanism of Action of Lead Program EVP-6124

12/05/2011
EnVivo Pharmaceuticals Presents Positive Comprehensive Phase 2b Study Results in Schizophrenia at American College of Neuropsychopharmacology Annual Meeting

10/31/2011
EnVivo Pharmaceuticals to Highlight Clinical Stage Program at Neuroscience 2011

06/27/2011
EnVivo Announces Initiation of Gamma Secretase Modulator Clinical Program in Alzheimer’s Disease

05/17/2011
EnVivo Announces Positive Phase 2b Clinical Data In Schizophrenia: EVP-6124 Meets Primary Endpoint with Statistically Significant Improvement in Cognition and Multiple Secondary Endpoints for Improvement in Function and Impact on Negative Symptoms

11/05/2010
EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist

07/14/2010
EnVivo Pharmaceuticals Announces Significant Results from GSM Transgenic Mouse Model for Alzheimer’s Disease

05/11/2010
EnVivo Initiates Phase IIb Alzheimer’s Disease Trial for EVP-6124

01/19/2010
Michael J. Fox Foundation Awards Research Grant to EnVivo as Part of Initiative Seeking New Parkinson’s Disease Treatments

01/05/2010
EnVivo Enters Phase 2b Trials for Its EVP-6124 Compound in the Treatment of Schizophrenia

12/08/2009
EnVivo Pharmaceuticals Announces Results Showing In-Vivo Reduction of Aggregated B-Amyloid

09/29/2009
EnVivo Pharmaceuticals names Stephen DiPalma Chief Financial Officer

07/15/2009
EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimer’s Disease

07/14/2009
EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer’s Disease Transgenic Mouse Model With Gamma-Secretase Modulator

04/01/2009
EnVivo and Mitsubishi-Tanabe Enter License Agreement on EVP-6124 In Japan, Korea, Taiwan and Other Asian Countries

01/12/2009
EnVivo Reports Positive Results of Its EVP-6124 Clinical Bio-Marker Study in Schizophrenia Patients

09/24/2008
EnVivo Pharmaceuticals Publishes Preclinical Data On EVP-0334

04/02/2008
Envivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in patients with Schizophrenia

02/06/2008
Methylgene Exercises Right to Opt-Out Of HDAC Neurodegenerative

10/17/2007
EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer’s, Schizophrenia and Huntington’s Diseases

09/25/2007
EnVivo Announces Hiring of Chief Medical Officer

11/16/2006
MethylGene and EnVivo Pharmaceuticals Form Collaboration with CHDI, Inc., in Support of HDAC Program for Huntington’s Disease

10/25/2006
EnVivo Pharmaceuticals Forms Research Collaboration With CHDI

10/04/2006
EnVivo Secures $24 Million in Series C Financing

05/23/2006
EnVivo Expands Management Team as Company Prepares First Drugs for Clinical Trials

06/27/2005
EnVivo Appoints Kees Been as Chief Executive Officer

11/09/2004
EnVivo Pharmaceuticals Secures $23 Million Series B Funding

08/17/2004
EnVivo Announces Hiring of Vice President of Chemistry

07/19/2004
MethylGene and EnVivo Pharmaceuticals to collaborate in Neurodegenerative Diseases

12/05/2003
EnVivo Appoints Several Leaders to Its Scientific Advisory Board

11/17/2003
EnVivo Announces Key Additions to Its Management Team

10/27/2003
EnVivo Pharmaceuticals Has Moved to Watertown, Massachusetts

10/06/2002
EnVivo Pharmaceuticals Closes $14.7M Series A Round Led by Fidelity BioSciences Group

10/01/2002
EnVivo Pharmaceuticals Awarded NIH Grant to Develop Technology for CNS Drug Discovery